Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14625827 | 0.86 | ALDH1A1 (0.61) | ALDH1A1PKMHPGDNPC1MEN1 | |
| SCHEMBL10591739 | 0.84 | ALDH1A1 (0.59) | ALDH1A1PKMHPGDNPC1MEN1 | |
| SCHEMBL13381593 | 0.81 | ALDH1A1 (0.56) | ALDH1A1PKMHPGDNPC1MEN1 | |
| SCHEMBL4466772 | 0.80 | ALDH1A1 (0.54) | ALDH1A1PKMHPGDNPC1MEN1 | |
| Hydrochloric Acid SCHEMBL4471373 | 0.80 | ALDH1A1 (0.54) | ALDH1A1PKMHPGDNPC1MEN1 | |
| SCHEMBL4093144 | 0.80 | ALDH1A1 (0.62) | ALDH1A1PKMHPGDNPC1MEN1 | |
| SCHEMBL5793985 | 0.80 | ALDH1A1 (0.62) | ALDH1A1PKMHPGDNPC1MEN1 | |
| SCHEMBL563548 | 0.79 | LMNA (0.50) | ALDH1A1HPGDNPC1MEN1KMT2A | |
| SCHEMBL13563626 | 0.79 | ALDH1A1 (0.53) | ALDH1A1PKMHPGDNPC1MEN1 | |
| SCHEMBL13563558 | 0.79 | ALDH1A1 (0.53) | ALDH1A1PKMHPGDNPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9085508-B2 | Nitric oxide releasing amino acid ester compound, composition and method of use | ORAL DELIVERY TECHNOLOGY LTD. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140057873-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | FARBER MICHAEL (US) | 2014-02-27 | — | — | US | disclosed |
| US-20110195935-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | BENOIT & COTE (CA) | 2011-08-11 | — | — | US | disclosed |
| EP-2342175-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | Nitrogenix Inc. (VG) | 2011-07-13 | — | — | EP | disclosed |
| US-7838023-B2 | Furoxan compounds, compositions and methods of use | NITROMED, INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-20090306027-A1 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF G-PROTEIN BETA 3 SUBUNIT POLYMORPHISM | NITOMED, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090053328-A1 | Nitric Oxide Enhancing Glutamic Acid Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090018091-A1 | Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2009-01-15 | — | — | US | disclosed |
| US-20090012057-A1 | Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use | NITROMED, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080306041-A1 | Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use | NICOX S.A. (FR) | 2008-12-11 | — | — | US | disclosed |
| US-20080268014-A1 | Furoxan Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-10-30 | — | — | US | disclosed |
| US-7396829-B2 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NITROMED, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20070238740-A1 | Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use | NITROMED, INC. (US) | 2007-10-11 | — | — | US | disclosed |
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070010571-A1 | Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use | NITROMED, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-20060189603-A1 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NITROMED, INC. (US) | 2006-08-24 | — | — | US | disclosed |
| US-20060009431-A1 | Nitrosated and nitrosylated compounds, compositions and methods use | NITROMED, INC. (US) | 2006-01-12 | — | — | US | disclosed |
| US-20050059655-A1 | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use | NITROMED, INC. (US) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010571-A1 | Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use | REN, ACE, AGTR1 | ALDH1A1 312/4885PKM 962/4885HPGD 121/4885 |
| US-20090012057-A1 | Cardiovascular Compounds Comprising Nitric Oxide Enhancing Groups, Compositions and Methods of Use | REN, EDNRB, ECE1 | ALDH1A1 1761/4885PKM 802/4885HPGD 100/4885 |
| US-20090053328-A1 | Nitric Oxide Enhancing Glutamic Acid Compounds, Compositions and Methods of Use | GLS, NOS1, NOS2 | ALDH1A1 1504/4885PKM 1196/4885HPGD 172/4885 |
| US-20060009431-A1 | Nitrosated and nitrosylated compounds, compositions and methods use | TBXA2R, TXNRD3, NOS3 | ALDH1A1 339/4885PKM 4647/4885HPGD 293/4885 |
| US-20080306041-A1 | Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use | REN, NOX5, NOS3 | ALDH1A1 468/4885PKM 765/4885HPGD 59/4885 |
| US-20110195935-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | NOS2, NOS3, NOS1 | ALDH1A1 1372/4885PKM 1280/4885HPGD 145/4885 |
| US-20090018091-A1 | Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use | NOS1, NOS3, NOS2 | ALDH1A1 1797/4885PKM 1569/4885HPGD 282/4885 |
| US-20070238740-A1 | Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use | REN, ECE1, EDNRA | ALDH1A1 1323/4885PKM 1629/4885HPGD 90/4885 |
| US-20050059655-A1 | Nitrosated and nitrosylated diuretic compounds, compositions and methods of use | REN, NOS1, NOS3 | ALDH1A1 396/4885PKM 1242/4885HPGD 60/4885 |
| US-20080268014-A1 | Furoxan Compounds, Compositions and Methods of Use | PTGIS, F3, PTGIR | ALDH1A1 681/4885PKM 2401/4885HPGD 355/4885 |
| US-20070032533-A1 | Nitric oxide enhancing angiotensin II antagonist compounds, compositions and methods of use | AGTR2, AGTR1, REN | ALDH1A1 2360/4885PKM 953/4885HPGD 259/4885 |
| US-20140057873-A1 | NITRIC OXIDE RELEASING AMINO ACID ESTER COMPOUND, COMPOSITION AND METHOD OF USE | NOS2, NOS3, NOS1 | ALDH1A1 1372/4885PKM 1280/4885HPGD 145/4885 |
| US-20060189603-A1 | such as 2H-1,2,4-benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-3-[5-(nitrooxy)pentyl]-, 1,1-dioxide; contains at least one nitric oxide enhancing group; excessive water or electrolyte retention conditions; cardiovascular diseases, and diseases resulting from oxidative or endothelial dysfunctions | NOS1, NOS3, REN | ALDH1A1 389/4885PKM 702/4885HPGD 71/4885 |
| US-20070037821-A1 | Nitrosated glutamic acid compounds, compositions and methods of use | GLS, NOS2, NOS1 | ALDH1A1 883/4885PKM 1013/4885HPGD 261/4885 |
| US-20090306027-A1 | GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF G-PROTEIN BETA 3 SUBUNIT POLYMORPHISM | ADRB3, GNAI3, GNB1 | ALDH1A1 1372/4885PKM 4542/4885HPGD 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.